Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96PZ2
UPID:
F111A_HUMAN
Alternative names:
-
Alternative UPACC:
Q96PZ2; A8K5Y8; Q5RKS9; Q5XKM2; Q68DK9; Q6IPR7; Q9H5Y1
Background:
Serine protease FAM111A plays a pivotal role in maintaining genomic integrity by mediating the proteolytic cleavage of covalent DNA-protein cross-links (DPCs) during DNA synthesis. These DPCs, induced by agents like UV light or formaldehyde, are highly toxic and interfere with crucial chromatin transactions. FAM111A ensures the smooth progression of replication and transcription by removing these obstacles, highlighting its essential function in DNA repair mechanisms.
Therapeutic significance:
FAM111A's involvement in diseases such as Kenny-Caffey syndrome 2 and Gracile bone dysplasia, characterized by skeletal abnormalities and hypocalcemia, underscores its potential as a therapeutic target. Understanding the role of Serine protease FAM111A could open doors to potential therapeutic strategies for these genetic disorders, offering hope for interventions that could mitigate their impact on affected individuals.